RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Stoke Therapeutics Stock

Stoke Therapeutics Market capitalization 2024

Stoke Therapeutics Market capitalization

536.3 M USD

Ticker

STOK

ISIN

US86150R1077

WKN

A2PLTL

In 2024, Stoke Therapeutics's market cap stood at 536.3 M USD, a 219.11% increase from the 168.06 M USD market cap in the previous year.

The Stoke Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.34
20220.6
20211.48
20201.03
20190.8
2018-
2017-

Stoke Therapeutics Aktienanalyse

What does Stoke Therapeutics do?

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Stoke Therapeutics's Market Capitalization

Stoke Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Stoke Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Stoke Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Stoke Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Stoke Therapeutics stock

What is the current Stoke Therapeutics market capitalization?

The current market capitalization of Stoke Therapeutics is 536.3 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Stoke Therapeutics.

How has the market capitalization of Stoke Therapeutics developed in recent years?

The market capitalization of Stoke Therapeutics has increased/decreased by 219.11% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Stoke Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Stoke Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Stoke Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Stoke Therapeutics in the year 2023?

In the year 2023, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Stoke Therapeutics

Our stock analysis for Stoke Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stoke Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.